{
  "version": 3,
  "created_at": "2026-07-10T17:43:58.236Z",
  "task_summary": "Fresh pitch deck, business plan, and AI-to-clinic scientific plan for Tolera Bio (EoE pMHC vaccine)",
  "agents": [],
  "phases": [
    {
      "name": "Plan",
      "delegations": [
        {
          "steps": [
            {
              "title": "Consolidate source material & brand assets",
              "description": "Pull and verify the brand brief (palette, company name Tolera Bio, founder, tagline, PACT platform naming), the financial model (Seed $8M / Series A $35M use-of-proceeds and milestone table), market sizing (TAM ~$2.2B, SAM ~55k, SOM ~8.3k/yr), and the market-access 'wrong-pocket' contracting models. Confirm which existing figures are reusable (platform_architecture, population_coverage, market_analysis, use_of_proceeds, milestone_timeline, market_access, landscape_matrix, outcomes_matrix, tzield_timeline) and identify gaps. No new artifact yet; produces a working brief in-kernel."
            },
            {
              "title": "Generate new supporting figures",
              "description": "Create 3-4 publication-grade figures in the brand palette (teal #1F7A8C / coral #E86A5C / graphite): (1) patient-priority → design-requirement mapping (the 5 cross-disease patient priorities mapped to Tolera design choices); (2) antigen-specific-vs-durable competitive whitespace 2x2 with EoE incumbents; (3) payer 'wrong-pocket' / value-based-pricing schematic showing outcomes-based annuity vs lifelong biologic cost; (4) AI-to-FIH scientific roadmap / assay-cascade schematic. Load figure-style first. Save as PNGs."
            },
            {
              "title": "Author the business plan document",
              "description": "Write a complete business plan (business_plan.md) folding in the market report: Executive Summary, Problem & Patient Journey, Solution (personalized pMHC-II tolerance vaccine + PACT platform), Market Analysis (TAM/SAM/SOM, epidemiology), Competitive Landscape & Whitespace, Patient-Centered Differentiation (the patient-voice-first thesis, PFDD gap), Business Model (therapeutic + companion diagnostic), Market Access & Reimbursement (wrong-pocket problem + 3 contracting models + go-to-market sequencing), Regulatory Strategy, Financials & Use of Proceeds, Milestones/Value Inflection, Team, Risks & Mitigations, and The Ask. Embed relevant figures."
            },
            {
              "title": "Author the scientific development plan",
              "description": "Write scientific_plan.md: the strongest technical approach to build and deliver the pMHC-II tolerance therapeutic, staged AI/ML modeling → first-in-patient. Cover (a) computational design engine (ESM-family sequence analysis, AlphaFold-multimer ipTM in-groove validation, HLA/epitope selection, antigen-selection strategy for plural EoE allergens); (b) in vitro assay cascade (recombinant pMHC-II expression/folding QC, SPR/thermal-stability binding, HLA-peptide binding, tetramer staining, antigen-specific T-cell functional assays — proliferation, cytokine/IL-10 Tr1 readouts, suppression assays); (c) delivery/formulation (tolerogenic nanoparticle, Signal-1 anergy + multivalent Tr1 induction, route/schedule); (d) preclinical package (humanized/murine PoC, GLP tox, NP biodistribution); (e) CMC & platform IND (shared backbone + swappable peptide cassette, N-of-1 release strategy); (f) companion diagnostic (HLA typing + allergen-sensitization + clonotype/remission monitor); (g) translational PD tolerance biomarker strategy and go/no-go gates. Explicitly thread the market-report lessons (biomarker-first, tolerogenic context not bare allergen, HLA stratification, early-disease population, anaphylaxis risk mitigation). Embed the assay-cascade roadmap figure."
            },
            {
              "title": "Render plans to PDF",
              "description": "Convert business_plan.md and scientific_plan.md to branded PDFs (via a markdown+CSS→HTML→PDF or pandoc route), with embedded figures and a cover header in the H&E/brand palette. Verify PDFs open and figures render. Save both markdown and PDF artifacts."
            },
            {
              "title": "Build the refreshed pitch deck",
              "description": "Generate Tolera_Bio_VC_Pitch_Deck_v2.pptx (16:9, brand palette) as a fresh ~14-16 slide VC deck reworked around the patient-centered thesis: Title; The Problem (patient journey + antigen-specific insight); Why Now; The Solution (pMHC-II tolerance vaccine); Platform (PACT, N-of-1 manufacturing); Scientific Validation (ipTM 0.87-0.90, dairy tetramer-validated); Competitive Whitespace; Patient-Voice-First differentiation (PFDD gap); Market Sizing; Business Model + Companion Dx; Market Access (wrong-pocket + contracting menu); Regulatory Roadmap (Tzield precedent); Development Plan / Milestones; Use of Proceeds; The Ask; Team/Vision. Reuse strong existing figures + the new ones."
            },
            {
              "title": "QC and package all deliverables",
              "description": "Verify the PPTX opens and slide count/images are intact; verify both PDFs render with figures; cross-check headline numbers ($8M Seed, $35M Series A, $2.2B TAM, ~$150k/course, ipTM 0.87-0.90, ~167,500 US prevalence) are consistent across all three deliverables. Save final artifacts (deck, both plans in md+pdf, new figures) and provide a summary with clickable links."
            }
          ]
        }
      ],
      "id": "phase-0"
    }
  ],
  "desired_outputs": [
    "Refreshed VC pitch deck (PPTX)",
    "Full business plan (markdown + rendered PDF)",
    "Scientific development plan: AI/ML → first-in-patient with assay cascade (markdown + rendered PDF)",
    "3-4 new supporting figures encoding patient/market/scientific-roadmap insights"
  ],
  "feasibility": {
    "rationale": "All source material exists in-project (market report, financial model, market-access strategy, regulatory analysis, patient voice, pMHC design validation, brand assets). The task is synthesis + document/deck generation, not new computation. Main effort is folding the patient-centered market report insights into cohesive, VC-grade deliverables and authoring a rigorous, assay-level scientific development plan.",
    "confidence": "high"
  }
}